380
Views
3
CrossRef citations to date
0
Altmetric
Review Articles

A Mini Review on Characteristics and Analytical Methods of Otilonium Bromide

ORCID Icon &
Pages 1717-1725 | Published online: 26 May 2021

References

  • Spinelli, A. Irritable Bowel Syndrome. Clin. Drug Investig. 2007, 27, 15–33. DOI: 10.2165/00044011-200727010-00002.
  • Andresen, V.; Camilleri, M. Irritable Bowel Syndrome: recent and Novel Therapeutic Approaches. Drugs 2006, 66, 1073–1088. DOI: 10.2165/00003495-200666080-00004.
  • Camilleri, M. Management Options for Irritable Bowel Syndrome. Mayo. Clin. Proc. 2018, 93, 1858–1872. DOI: 10.1016/j.mayocp.2018.04.032.
  • Grayson, M. Irritable Bowel Syndrome. Nature 2016, 533, S101. DOI: 10.1038/533S101a.
  • Tack, J.; Fried, M.; Houghton, L. A.; Spicak, J.; Fisher, G. Systematic Review: The Efficacy of Treatments for Irritable Bowel Syndrome–a European Perspective. Aliment. Pharmacol. Ther. 2006, 24, 183–205. DOI: 10.1111/j.1365-2036.2006.02938.x.
  • Longstreth, G. F.; Thompson, W. G.; Chey, W. D.; Houghton, L. A.; Mearin, F. Spiller, R.C. Functional Bowel Disorders. Gastroenterology 2006, 130, 1480–1491. DOI: 10.1053/j.gastro.2005.11.061.
  • Ford, A. C.; Lacy, B. E.; Talley, N. J. Irritable Bowel Syndrome. N. Engl. J. Med. 2017, 376, 2566–2578. DOI: 10.1056/NEJMra1607547.
  • Chey, W. D.; Kurlander, J.; Eswaran, S. Irritable Bowel Syndrome: A Clinical Review. JAMA 2015, 313, 949–958. DOI: 10.1001/jama.2015.0954.
  • Boeckxstaens, G.; Corazziari, E. S.; Mearin, F.; Tack, J. IBS and the Role of Otilonium Bromide. Int. J. Colorectal Dis. 2013, 28, 295–304. DOI: 10.1007/s00384-012-1598-0.
  • Evangelista, S. Quaternary Ammonium Derivatives as Spasmolytics for Irritable Bowel Syndrome. Curr. Pharm. Des. 2004, 10, 3561–3568. DOI: 10.2174/1381612043382972.
  • García-Alvarado, F.; Govoni, G.; de Pascual, R.; Ruiz-Ruiz, C.; Muñoz-Montero, A.; Gandía, L.; de Diego, A. M. G.; García, A. G. Otilonium and Pinaverium Trigger Mitochondrial-Mediated Apoptosis in Rat Embryo Cortical Neurons in Vitro. Neurotoxicology 2019, 70, 99–111. DOI: 10.1016/j.neuro.2018.11.003.
  • Otilonium bromide. Chemspider. Royal Society of Chemistry http://www.chemspider.com/Chemical-Structure.65077.html. (accessed 03,30,2021).
  • Traini, C.; Evangelista, S.; Girod, V.; Faussone-Pellegrini, M. S.; Vannucchi, M. G. Repeated Otilonium Bromide Administration Prevents Neurotransmitter Changes in Colon of Rats Underwent to Wrap Restraint Stress. J. Cell. Mol. Med 2017, 21, 735–745. DOI: 10.1111/jcmm.13016.
  • Knauf, G. A.; Cunningham, A. L.; Kazi, M. I.; Riddington, I. M.; Crofts, A. A.; Cattoir, V.; Trent, M. S.; Davies, B. W. Exploring the Antimicrobial Action of Quaternary Amines against Acinetobacter baumannii. MBio 2018, 9, 17. e02394- DOI: 10.1128/mBio.02394-17.
  • Martínez-Cutillas, M.; Gil, V.; Gallego, D.; Mañé, N.; Martín, M. T.; Jiménez, M. Mechanisms of Action of Otilonium Bromide (OB) in Human Cultured Smooth Muscle Cells and Rat Colonic Strips. Neurogastroenterol. Motil 2013, 25, e803. 12. DOI: 10.1111/nmo.12206.
  • Filipski, K. J.; Varma, M. V.; El-Kattan, A. F.; Ambler, C. M.; Ruggeri, R. B.; Goosen, T. C.; Cameron, K. O. Intestinal Targeting of Drugs: rational Design Approaches and Challenges. Curr. Top Med. Chem 2013, 13, 776–802. DOI: 10.2174/1568026611313070002.
  • Evangelista, S. Otilonium Bromide: A Selective Spasmolytic for the Gastrointestinal Tract. J. Int. Med. Res 1999, 27, 207–222. DOI: 10.1177/030006059902700501.
  • Ivey, K. J. Are Anticholinergics of Use in the Irritable Colon Syndrome? Gastroenterology 1975, 68, 1300– 1307. DOI: 10.1016/S0016-5085(75)80249-6.
  • Greenblatt, D. J.; Shader, R. I. Drug Therapy. Anticholinergics. N. Engl. J. Med 1973, 288, 1215–1219. DOI: 10.1056/NEJM197306072882306.
  • Munjal, A.; Dedania, B.; Cash, B. D. Current and Emerging Pharmacological Approaches for Treating Diarrhea-Predominant Irritable Bowel Syndrome. Expert Opin. Pharmacother 2020, 21, 63–71. DOI: 10.1080/14656566.2019.1691524.
  • Gibbons, S. J.; Strege, P. R.; Lei, S.; Roeder, J. L.; Mazzone, A.; Ou, Y.; Rich, A.; Farrugia, G. The 1H Ca2+ Channel Subunit is Expressed in Mouse Jejunal Interstitial Cells of Cajal and Myocytes. J. Cell. Mol. Med 2009, 13, 4422–4431. DOI: 10.1111/j.1582-4934.2008.00623.x.
  • Lee, H. T.; Hennig, G. W.; Fleming, N. W.; Keef, K. D.; Spencer, N. J.; Ward, S. M.; Sanders, K. M.; Smith, T. K. The Mechanism and Spread of Pacemaker Activity through Myenteric Interstitial Cells of Cajal in Human Small Intestine. Gastroenterology 2007, 132, 1852–1865. DOI: 10.1053/j.gastro.2007.02.049.
  • Rich, A.; Farrugia, G.; Sarr, M. G.; Szurszewski, J. H. Calcium Currents in Interstitial Cells from Human Jejunum. Gastroenterology 1998, 114, A826. DOI: 10.1016/S0016-5085(98)83367-2.
  • De Ponti, F.; Giaroni, C.; Cosentino, M.; Lecchini, S.; Frigo, G. Calcium-Channel Blockers and Gastrointestinal Motility: basic and Clinical Aspects. Pharmacol. Ther 1993, 60, 121–148. DOI: 10.1016/0163-7258(93)90024-8.
  • Strege, P. R.; Evangelista, S.; Lyford, G. L.; Sarr, M. G.; Farrugia, G. Otilonium Bromide Inhibits Calcium Entry through L-Type Calcium Channels in Human Intestinal Smooth Muscle. Neurogastr. Motil 2004, 16, 167–174. DOI: 10.1111/j.1365-2982.2004.00517.x.
  • Strege, P. R.; Sha, L.; Beyder, A.; Bernard, C. E.; Perez-Reyes, E.; Evangelista, S.; Gibbons, S. J.; Szurszewski, J. H.; Farrugia, G. T-Type Ca2+ Channel Modulation by Otilonium Bromide. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G706–13. DOI: 10.1152/ajpgi.00437.2009.
  • Lindqvist, S.; Hernon, J.; Sharp, P.; Johns, N.; Addison, S.; Watson, M.; Tighe, R.; Greer, S.; Mackay, J.; Rhodes, M.; et al. The Colon-Selective Spasmolytic Otilonium Bromide Inhibits Muscarinic M(3) Receptor-Coupled Calcium Signals in Isolated Human Colonic Crypts. Br. J. Pharmacol 2002, 137, 1134–1142. DOI: 10.1038/sj.bjp.0704942.
  • Barbalho, S. M.; Souza, M. S. S.; Goulart, R. A.; Gasparini, R. G.; Carvalho, A. C. A. Irritable Bowel Syndrome: pathophysiological and Pharmacological Aspects and Use of Otilonium Bromide or Pinaverium Bromide. Pharmacologyonline 2015, 3, 53–61.
  • Clavé, P.; Tack, J. Efficacy of Otilonium Bromide in Irritable Bowel Syndrome: A Pooled Analysis. Therap. Adv. Gastroenterol 2017, 10, 311–322. DOI: 10.1177/1756283X16681708.
  • Evangelista, S.; Cochet, P.; Bromet, N.; Criscuoli, M.; Maggi, C. A. A Distribution Study with 14C-Otilonium Bromide in the Rat: evidence for Selective Tropism for Large Intestine after Oral Administration. Drug Metab. Disp 2000, 28, 643–647.
  • Ghelardoni, M.; Pestellini, V.; Pisanti, N.; Volterra, G. Quaternary Salts of Substituted 2-Aminoethyl N-Benzoylaminobenzoate. A New Class of Smooth Muscle Relaxant Agents. J. Med. Chem 1973, 16, 1063–1065. DOI: 10.1021/jm00267a029.
  • Chunxiang, J.; Tao, W.; Huang, F.; Wenbin, C.; Jingxin, S. Xiaofei, Preparation method of otilonium bromide. Patent CN105037193A, filled August 2015.
  • Shah, V. P.; Midha, K. K.; Dighe, S.; McGilveray, I. J.; Skelly, J. P.; Yacobi, A.; Layloff, T.; Viswanathan, C. T.; Cook, C. E.; McDowall, R. D.; et al. Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies. J. Pharm. Sci. 1992, 81, 309–312. DOI: 10.1002/jps.2600810324.
  • Siddiqui, M. R.; AlOthman, Z. A.; Rahman, N. Analytical Techniques in Pharmaceutical Analysis: A Review. Arabian J. Chem. 2017, 10, 1, S1409–S1421. DOI: 10.1016/j.arabjc.2013.04.016.
  • Bridwell, H.; Dhingra, V.; Peckman, D.; Roark, J.; Lehman, T. Perspectives on Method Validation: Importance of Adequate Method Validation. Qual. Assur. J. 2010, 13, 72–77. DOI: 10.1002/qaj.473.
  • Vieira, L. E. M.; Vieira, F. P.; Ávila‐Terra, L. H. S.; Gaubeur, I.; Guekezian, M.; Suárez‐Iha, M. E. V. Spectrophotometric Determination of Zinc in Pharmaceutical and Biological Samples with Di‐2‐Pyridyl Ketone Benzoylhydrazone: A Simple, Fast, Accurate and Sensitive Method. Anal. Lett. 2008, 41, 779–788. DOI: 10.1080/00032710801934841.
  • Walker, J. T. The Applications of Spectrophotometry to Medicine. N. Engl. J. Med 1949, 240, 200–202. DOI: 10.1056/NEJM194902032400512.
  • Mannucci, C.; Bertini, J.; Cocchini, A.; Perico, A.; Salvagnini, F.; Triolo, A. Simultaneous Determination of Otilonium Bromide and Diazepam by First-Derivative Spectroscopy. J. Pharm. Sci. 1992, 81, 1175–1177. DOI: 10.1002/jps.2600811209.
  • Morelli, B. Determination of Diazepam and Otilonium Bromide in Pharmaceuticals by Ratio-Spectra Derivative Spectrophotometry. Fresenius J. Anal. Chem. 1997, 357, 1179–1184. DOI: 10.1007/s002160050327.
  • el-Kousy, N. M.; Bebawy, L. I. Stability-Indicating Methods for Determining Omeprazole and Octylonium Bromide in the Presence of Their Degradation Products. J. AOAC Int. 1999, 82, 599–606. DOI: 10.1093/jaoac/82.3.599.
  • Blanco, M.; Coello, J.; Iturriaga, H.; Maspoch, S.; Pou, N. Development and Validation of a near Infrared Method for the Analytical Control of a Pharmaceutical Preparation in Three Steps of the Manufacturing Process. Fresenius J. Anal. Chem. 2000, 368, 534–539. DOI: 10.1007/s002160000506.
  • Bilek, M.; Namieśnik, J. Chromatographic Techniques in Pharmaceutical Analysis in poland: history and the Presence on the Basis of Papers Published in Selected Polish Pharmaceutical Journals in XX Century. Acta Pol. Pharm. 2016, 73, 605–612.
  • Partridge, M. W. Chromatography and Its Applications in Pharmacy. J. Pharm. Pharmacol. 1952, 4, 217–230. DOI: 10.1111/j.2042-7158.1952.tb13137.x.
  • Hirtz, J. Importance of Analytical Methods in Pharmacokinetic and Drug Metabolism Studies. Biopharm. Drug Dispos. 1986, 7, 315–326. DOI: 10.1002/bdd.2510070402.
  • Mannucci, C.; Bertini, J.; Cocchini, A.; Perico, A.; Salvagnini, F.; Triolo, A. High-Performance Liquid Chromatographic Method for Assay of Otilonium Bromide, Diazepam, and Related Compounds in Finished Pharmaceutical Forms. J. Pharm. Sci. 1993, 82, 367–370. DOI: 10.1002/jps.2600820406.
  • Tie, Z.; Shao-Jie, W.; Zhong-Gui, H.; Ling-Yan, J.; Ying-Hong, X. Ion Pair HPLC Determination of Otilonium Bromide and Its Related Substance. Chinese J. Pharm. Anal. 2006, 26, 1500–1502.
  • Shin, B. S.; Kim, J. J.; Kim, J.; Hu, S. K.; Kim, H. J.; Hong, S. H.; Kim, H. K.; Lee, H. S.; Yoo, S. D. Oral Bioavailability and Enterohepatic Recirculation of Otilonium Bromide in Rats. Arch. Pharm. Res. 2008, 31, 117–124. DOI: 10.1007/s12272-008-1129-2.
  • Catalioto, R. M.; Triolo, A.; Giuliani, S.; Altamura, M.; Evangelista, S.; Maggi, C. A. Increased Paracellular Absorption by Bile Salts and P-Glycoprotein Stimulated Efflux of Otilonium Bromide in Caco-2 Cells Monolayers as a Model of Intestinal Barrier. J. Pharm. Sci. 2008, 97, 4087–4100. DOI: 10.1002/jps.21240.
  • Zhao, Y. R.; Ding, L.; Fan, H. W.; Yu, Y.; Qi, X. M.; Leng, Y.; Rao, Y. K. Determination of the Unstable Drug Otilonium Bromide in Human Plasma by LC-ESI-MS and Its Application to a Pharmacokinetic Study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878, 2896–2900. DOI: 10.1016/j.jchromb.2010.08.003.
  • El-Kerdawy, M.; El-Bagary, R.; Elkady, E.; Othman, A. Development and Validation of a Stability-Indicating RP-LC Method for the Simultaneous Determination of Otilonium Bromide and Its Expected Degradation Product in Bulk Drug and Pharmaceutical Preparation. Eur. J. Chem. 2016, 7, 97–101. DOI: 10.5155/eurjchem.7.1.97-101.1358.
  • Furlanetto, S.; Orlandini, S.; Massolini, G.; Faucci, M. T.; La Porta, E.; Pinzauti, S. Optimisation and Validation of a Capillary Electrophoresis Method for the Simultaneous Determination of Diazepam and Otilonium Bromide. Analyst 2001, 126, 1700–1706. DOI: 10.1039/b103091b.
  • Pudipeddi, M.; Serajuddin, A. T. Trends in Solubility of Polymorphs. J. Pharm. Sci. 2005, 94, 929–939. DOI: 10.1002/jps.20302.
  • Dapporto, P.; Sega, A. Diethylmethyl{2-[p-(o-Octyloxybenzamido)Benzoyloxy]Ethyl} Ammonium Bromide (I) and Diethylmethyl{2-[p-(o-Propyloxybenzamido) Benzoyloxy]Ethyl}Ammonium Bromide (II). Acta Crystallogr. C Cryst. Struct. Commun. 1986, 42, 474–478. DOI: 10.1107/S0108270186095744.
  • Vega, D. R.; Halac, E.; Segovia, L.; Baggio, R. A New, More Stable Polymorphic Form of Otilonium Bromide: Solubility, Crystal Structure, and Phase Transformation. J. Pharm. Sci. 2016, 105, 3013–3020. DOI: 10.1016/j.xphs.2016.06.012.
  • Płotka-Wasylka, J.; Gałuszka, A.; Namieśnik, J. Green Analytical Chemistry: Summary of Existing Knowledge and Future Trends. In Green Analytical Chemistry, Green Chemistry and Sustainable Technology, Płotka-Wasylka, J., Namiésnik, J., Eds.; Springer: Singapore, 2019. DOI: 10.1007/978-981-13-9105-7_15.
  • Gałuszka, A.; Migaszewski, Z.; Namieśnik, J. The 12 Principles of Green Analytical Chemistry and the Significance Mnemonic of Green Analytical Practices. Trends Analyt. Chem. 2013, 50, 78–84. DOI: 10.1016/j.trac.2013.04.010.
  • Billiard, K. M.; Dershem, A. R.; Gionfriddo, E. Implementing Green Analytical Methodologies Using Solid-Phase Microextraction: A Review. Molecules 2020, 25, 5297. DOI: 10.3390/molecules25225297.
  • Ranjbar, S.; Seyednejad, S. A.; Nikfar, S.; Rahimi, R.; Abdollahi, M. How Can we Develop Better Antispasmodics for Irritable Bowel Syndrome? Expert Opin. Drug Discov. 2019, 14, 549–562. DOI: 10.1080/17460441.2019.1593369.
  • Zhou, L.; She, P.; Tan, F.; Li, S.; Zeng, X.; Chen, L.; Luo, Z.; Wu, Y. Repurposing Antispasmodic Agent Otilonium Bromide for Treatment of Staphylococcus aureus Infections. Front Microbiol. 2020, 11, 1720. DOI: 10.3389/fmicb.2020.01720.
  • Triantafillidis, J.; Malgarinos, G. Long-Term Efficacy and Safety of Otilonium Bromide in the Management of Irritable Bowel Syndrome: A Literature Review. Clin. Exp. Gastroenterol. 2014, 7, 75–82. DOI: 10.2147/CEG.S46291.
  • Bodson, C.; Rozet, E.; Ziemons, E.; Evrard, B.; Hubert, P.; Delattre, L. Validation of Manufacturing Process of Diltiazem HCl Tablets by NIR Spectrophotometry (NIRS). J. Pharm. Biomed. Anal. 2007, 45, 356–361. DOI: 10.1016/j.jpba.2007.05.015.
  • Shewiyo, D. H.; Kaale, E.; Risha, P. G.; Dejaegher, B.; Smeyers-Verbeke, J. Vander Heyden, Y. HPTLC Methods to Assay Active Ingredients in Pharmaceutical Formulations: A Review of the Method Development and Validation Steps. J. Pharm. Biomed. Anal. 2012, 66, 11–23. DOI: 10.1016/j.jpba.2012.03.034.
  • Hejmady, S.; Choudhury, D.; Pradhan, R.; Singhvi, G.; Dubey, S. K. Analytical quality by design for high-performance thin-layer chromatography method development. In Handbook of Analytical Quality by Design, Beg, S., Md, S.H., Rahman, M., Almalki, W.H., Eds.; Academic Press: United Kingdom, 2021. DOI: 10.1016/B978-0-12-820332-3.00007-8.
  • Crowley, T. E. High-Performance Liquid Chromatography. In Purification and Characterization of Secondary Metabolites, Crowley, T.E., Ed.; Academic Press: United Kingdom, 2020; pp. 49–58. DOI: 10.1016/B978-0-12-813942-4.00005-X.
  • Lankelma, J.; van Iperen, D. J.; van der Sluis, P. J. Towards Using High-Performance Liquid Chromatography at Home. J. Chromatogr. A 2021, 1639, 461925. 1639, DOI: 10.1016/j.chroma.2021.461925.
  • Lozano-Sánchez, J.; Borrás-Linares, I.; Sass-Kiss, A.; Segura-Carretero, A. Chromatographic Technique: High-Performance Liquid Chromatography (HPLC). Modern Techniques for Food Authentication, Da-Wen, S., Ed.; Academic Press: United Kingdom, 2018. DOI: 10.1016/B978-0-12-814264-6.00013-X.
  • LaCourse, M. E.; LaCourse, W. R. General Instrumentation in HPLC. In Liquid Chromatography, Fanali, S. Haddad, P.R., Poole, C.F., Marja-Liisa R., Eds.; Elsevier; Amsterdam, Netherlands, 2017; pp. 417–429. DOI: 10.1016/B978-0-12-805393-5.00017-8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.